Physiomics Plc (LSE:PYC) — Market Cap & Net Worth
Market Cap & Net Worth: Physiomics Plc (PYC)
Physiomics Plc (LSE:PYC) has a market capitalization of $28.95K (GBX237.93 Million) as of June 19, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31493 globally and #1250 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Physiomics Plc's stock price GBX0.53 by its total outstanding shares 453208718 (453.21 Million). Review Physiomics Plc (PYC) total liabilities to assess the company's total debt and financial obligations.
Physiomics Plc Market Cap History: 2015 to 2026
Physiomics Plc's market capitalization history from 2015 to 2026. Data shows change from $193.00K to $28.95K (-19.76% CAGR).
Index Memberships
Physiomics Plc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$939.61 Million | 0.00% | #442 of 722 |
Weight: Physiomics Plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Physiomics Plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Physiomics Plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
Physiomics Plc's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $107.53K | $297.12K | -$378.70K | 0.36x | N/A |
| 2017 | $448.03K | $270.46K | -$400.53K | 1.66x | N/A |
| 2018 | $209.54K | $512.90K | -$183.34K | 0.41x | N/A |
| 2019 | $190.24K | $783.10K | -$104.04K | 0.24x | N/A |
| 2020 | $405.30K | $799.05K | -$64.42K | 0.51x | N/A |
| 2021 | $358.43K | $702.31K | -$215.83K | 0.51x | N/A |
| 2022 | $157.16K | $830.27K | -$253.14K | 0.19x | N/A |
| 2023 | $88.23K | $597.35K | -$477.26K | 0.15x | N/A |
| 2024 | $41.36K | $543.25K | -$609.35K | 0.08x | N/A |
| 2025 | $15.72K | $784.00K | -$415.25K | 0.02x | N/A |
Competitor Companies of PYC by Market Capitalization
Companies near Physiomics Plc in the global market cap rankings as of June 19, 2026.
Key companies related to Physiomics Plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Physiomics Plc Historical Marketcap From 2015 to 2026
Between 2015 and today, Physiomics Plc's market cap moved from $193.00K to $ 28.95K, with a yearly change of -19.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX28.95K | +84.21% |
| 2025 | GBX15.72K | -62.00% |
| 2024 | GBX41.36K | -53.12% |
| 2023 | GBX88.23K | -43.86% |
| 2022 | GBX157.16K | -56.15% |
| 2021 | GBX358.43K | -11.56% |
| 2020 | GBX405.30K | +113.04% |
| 2019 | GBX190.24K | -9.21% |
| 2018 | GBX209.54K | -53.23% |
| 2017 | GBX448.03K | +316.67% |
| 2016 | GBX107.53K | -44.29% |
| 2015 | GBX193.00K | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Physiomics Plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $28.95K USD |
| MoneyControl | $28.95K USD |
| MarketWatch | $28.95K USD |
| marketcap.company | $28.95K USD |
| Reuters | $28.95K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Physiomics Plc
Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour pred… Read more